{"denoms":[{"counts":[{"groupId":"BG000","value":"51"},{"groupId":"BG001","value":"95"},{"groupId":"BG002","value":"88"},{"groupId":"BG003","value":"234"}],"units":"Participants"}],"groups":[{"description":"Placebo sc injection Q2W.\n\nTreatment received from Week 16 - 48 was based on initial treatment and response to treatment:\n\n* PASI50 responders at Week 16, who did not achieve a PASI75 response at Week 16 received CZP 400 mg at Weeks 16, 18 and 20 (loading doses) followed by CZP 200 mg Q2W starting at Week 22.\n* PASI75 responders at Week 16 continued to receive Placebo.\n* PASI50 non-responders at Week 16 were removed from blinded study medication and escaped to unblinded CZP 400 mg Q2W. Participants who received unblinded CZP 400 mg Q2W for 16 weeks and did not achieve a PASI50 response were withdrawn from the study.\n* PASI50 non-responders at Week 32 or a later time point were withdrawn from the study.\n\nParticipants who completed the Maintenance Period (with PASI50 response at Week 48) entered the Open-label Extension (OLE) Period on CZP 200 mg Q2W. Week 48 completers in the escape arm continued to receive CZP 400 mg Q2W or may have switched to CZP 200 mg Q2W.","id":"BG000","title":"Placebo Q2W"},{"description":"CZP 400 mg at Weeks 0, 2, 4, followed by CZP 200 mg Q2W from Week 6 to Week 14.\n\nTreatment received from Week 16 - 48 was based on initial treatment and response to treatment:\n\n* PASI50 responders at Week 16 continued to receive CZP 200 mg Q2W.\n* PASI50 non-responders at Week 16 were removed from blinded study medication and escaped to unblinded CZP 400 mg Q2W. Participants who received unblinded CZP 400 mg Q2W for 16 weeks and did not achieve a PASI50 response were withdrawn from the study.\n* PASI50 non-responders at Week 32 or a later time point were withdrawn from the study.\n\nParticipants who completed the Maintenance Period (with PASI50 response at Week 48) entered the OLE Period on CZP 200 mg Q2W.\n\nWeek 48 completers in the escape arm continued to receive CZP 400 mg Q2W or may have switched to CZP 200 mg Q2W.\n\nDepending on PASI50 or PASI75 responses at Week 60 or a later time point, participants may have switched to CZP 400 mg Q2W or withdrew from the study.","id":"BG001","title":"CZP 200 mg Q2W"},{"description":"CZP 400 mg Q2W through Week 14.\n\nTreatment received from Week 16 - 48 was based on initial treatment and response to treatment:\n\n* PASI50 responders at Week 16 continued to receive CZP 400 mg Q2W.\n* PASI50 non-responders at Week 16 were removed from blinded study medication and escaped to unblinded CZP 400 mg Q2W. Participants who received unblinded CZP 400 mg Q2W for 16 weeks and did not achieve a PASI50 response were withdrawn from the study.\n* PASI50 non-responders at Week 32 or a later time point were withdrawn from the study.\n\nParticipants who completed the Maintenance Period (with PASI50 response at Week 48) entered the OLE Period on CZP 200 mg Q2W. Week 48 completers in the escape arm continued to receive CZP 400 mg Q2W or may have switched to CZP 200 mg Q2W.\n\nParticipants who achieved a PASI75 response during the OLE Period may have switched to CZP 200 mg Q2W.","id":"BG002","title":"CZP 400 mg Q2W"},{"id":"BG003","title":"Total Title"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"45"},{"groupId":"BG001","value":"90"},{"groupId":"BG002","value":"86"},{"groupId":"BG003","value":"221"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"13"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"12.8","value":"47.9"},{"groupId":"BG001","spread":"13.1","value":"44.5"},{"groupId":"BG002","spread":"12.1","value":"43.6"},{"groupId":"BG003","spread":"12.7","value":"44.9"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"28"},{"groupId":"BG003","value":"72"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"35"},{"groupId":"BG001","value":"67"},{"groupId":"BG002","value":"60"},{"groupId":"BG003","value":"162"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"Baseline Characteristics refer to the Randomized Set, which consisted of all participants randomized into the study."}